Access EIS investments for August 2023

SyndicateRoom logo
Syndicate Room
11 September 20232 min read

In August we added two startups to the Access portfolio, co-investing alongside one of our angel investors in each case (for more on our super angels and our co-investment model, see our dedicated page).

Read on for more about our latest investments. If you would like to receive this update each month, sign up for our newsletter here.

Pencil Biosciences

Pencil Biosciences is developing an innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases.

Pencil Biosciences

Angel: Our angel partner in the round has a weighted IRR of 34% and has previously invested in companies including Celixir, Sense Biodetection and Bank of Telecom.

Total Round: approx. £700,000

Visit website

Name currently witheld

This company has created a network for employee referrals. They've asked us not to give any further details until their own press goes live.

Angel: Our angel partner in the round has a weighted IRR of 32% and has previously invested in The Plum Guide, Plentific & Learnerbly

Total Round: approx. £730,000.

Find out more about how the Access EIS Fund can work for you. You can click the button below to schedule a call, or call us on 01223 478 558 and we'll be happy to answer any questions you might have.

Schedule a call with us.

Award
What is Access EIS?
Read our fund brochure for everything you need to know about the Access EIS Fund, from the specifics of our innovative co-investment model to our fees, and how to invest.

Risk warning: Please click here to read the full risk warning.
Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
This page has been approved as a financial promotion by Syndicate Room Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 613021).
We use cookies to improve our service. By continuing to use this site you are agreeing to their use. Find out more.
Please provide your email and/or phone number and we'll get back to you as soon as possible.
Access EIS investments for August 2023